ClinicalTrials.gg
RecruitingNCT06413680BrILlianceUpdated Apr 28, 2026

A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body

A Phase 1/2 interventional study of REGN10597 and Cemiplimab in Melanoma, Clear-Cell Renal-Cell Carcinoma (ccRCC) and Advanced Solid Tumors, sponsored by Regeneron Pharmaceuticals. Recruiting at 11 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-28.

Sponsored by Regeneron Pharmaceuticals · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
240
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies testing cemiplimab in Melanoma — 6 open to participants now, 9 under way, 1 of them phase 3. cemiplimab · Melanoma.

Planned enrollment
2nd of 11
240 · median 87
Started
2024
with 3 others
Phase 1/2
Only one
of the 11
Registered
6th of 11
by date
Lead sponsor
5 of 11
Regeneron Pharmaceuticals

Among the 11 studies testing cemiplimab in Melanoma, this one is the 2nd largest by planned enrollment, is one of 4 that started in 2024, is the only one in phase 1/2, and was the 6th registered.

Melanoma

3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.

Browse Melanoma studies →

Open to participants now

6 of the 11 studies testing cemiplimab in Melanoma are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About cemiplimab

cemiplimab: first FDA approval 2018 (LIBTAYO), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 468 Melanoma studies recruiting now, 381 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing cemiplimab in Melanoma, or all of them as a file.
02

Study summary

This study is researching an experimental drug called REGN10597 alone or in combination with another drug called cemiplimab (called "study drug(s)"). The study is focused on patients with certain solid tumors that are in an advanced stage.

The aim of the study is to see how safe, tolerable, and effective the study drug(s) are.

The study is looking at several other research questions, including:

  • What side effects may happen from taking the study drug(s)
  • How much study drug(s) is in the blood at different times
  • Whether the body makes antibodies against the study drug(s) (which could make the study drug(s) less effective or could lead to side effects)
Read the detailed description

Phase 1: Conducted in the United States only Phase 2: Conducted globally

03

Conditions studied

  • Melanoma
  • Clear-Cell Renal-Cell Carcinoma (ccRCC)
  • Advanced Solid Tumors

Keywords

  • Advanced solid organ malignancies
  • Locally advanced
  • Metastatic
  • Non-uveal
  • Unresectable
  • Primary or secondary resistance to programmed cell death protein 1 (PD-1)/ programmed cell death ligand 1 (PD-L1)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

Dose escalation cohorts:

1. or cytologically confirmed diagnosis of solid (locally advanced or ) with confirmed progression on standard-of-care therapy. Participants are required to submit if it is available

Dose expansion cohorts:

1. Histologically of cytologically confirmed diagnosis of one of the following tumors with criteria, as defined in the protocol:

  • Module 1, Cohort 1: anti-PD-(L)1 Progressed Melanoma or
  • Module 1, Cohort 2: anti-PD-(L)1 Progressed RCC or
  • Module 2, Cohort 1: 1L Melanoma ALL Participants ARE REQUIRED to submit fresh pretreatment biopsy during screening, with an additional exploratory biopsy at other time points

Key Exclusion Criteria:

  1. Prior treatment with Interleukin 2 (IL2)/IL15/IL-7 given outside the context of concurrent administration with adoptive cell therapy
  2. Prior treatment with anti-PD1/, or an approved systemic therapy or any previous systemic non-immunomodulatory biologic therapy within 4 weeks, as defined in the protocol
  3. Has received radiation therapy or major surgery within 14 days prior to first dose of study drug or has not yet recovered from AEs
  4. Has had prior anti-cancer immunotherapy within 4 weeks prior to study intervention, or discontinuation of prior anti-cancer immunotherapy due to grade 3 or 4 toxicities
  5. Has ongoing immune-related AEs prior to initiation of study intervention, as defined in the protocol
  6. Has known allergy or to components of the study drug(s)
  7. Has any condition requiring ongoing/continuous therapy (>10 mg prednisone/day or anti-inflammatory equivalent) within 1-2 weeks to the first dose of study intervention
  8. Has ongoing or recent (within 5 years) evidence of significant disease or any other condition that required treatment with systemic treatments

NOTE: Other Protocol Defined Inclusion / Exclusion Criteria Apply.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    Phase 1: Monotherapy Dose Escalation

    Multiple Dose Level (DL) Cohorts to identify the Recommended Phase 2 Dose (RP2D)

    Drug: REGN10597

  • Experimental
    Phase 2: Monotherapy Dose Expansion

    Cohort 1: Melanoma participants Cohort 2: Clear-cell Renal-Cell Carcinoma (ccRCC) participants

    Drug: REGN10597

  • Experimental
    Phase 1: Combination Dose Escalation

    Multiple DL Cohorts to identify the RP2D

    Drug: REGN10597 · Drug: Cemiplimab

  • Experimental
    Phase 2: Combination Dose Expansion

    Cohort 1: Melanoma participants

    Drug: REGN10597 · Drug: Cemiplimab

Interventions

  • DrugREGN10597

    Administered per the protocol

  • Administered per the protocol

06

What researchers measure

Primary outcomes

  1. Incidence of Dose-Limiting Toxicities (DLTs)

    Dose escalation

    Time frame: Up to Day 29

  2. Incidence of Treatment-Emergent Adverse Event (TEAEs)

    Dose escalation

    Time frame: Approximately 6 Years

  3. Incidence of Serious Adverse Events (SAEs)

    Dose escalation

    Time frame: Approximately 6 Years

  4. Incidence of TEAEs leading to treatment discontinuation

    Dose escalation

    Time frame: Approximately 6 Years

  5. Incidence of TEAEs leading to death

    Dose escalation

    Time frame: Approximately 6 Years

  6. Number of participants with Grade 3 laboratory abnormalities

    Dose escalation Grade 3 or higher per Common Terminology Criteria for Adverse Events (CTCAE) version 5.0

    Time frame: Approximately 6 Years

  7. Objective Response Rate (ORR) per Response Evaluation Criteria In Solid Tumors (RECIST 1.1) criteria by investigator assessment

    Dose expansion

    Time frame: Approximately 6 Years

Secondary outcomes

  1. ORR based on RECIST 1.1 criteria by investigator assessment

    Dose escalation

    Time frame: Approximately 6 Years

  2. Best Overall Response (BOR) based on RECIST 1.1 criteria

    Time frame: Approximately 6 Years

  3. Duration Of Response (DOR) based on RECIST 1.1 criteria

    Time frame: Approximately 6 Years

  4. Disease control rate based on RECIST 1.1

    Time frame: Approximately 6 Years

  5. Time to response based on RECIST 1.1

    Time frame: Approximately 6 Years

  6. Progression Free Survival (PFS) based on RECIST 1.1

    Time frame: Approximately 6 Years

  7. Concentrations of REGN10597 in serum

    Time frame: Approximately 6 Years

  8. Incidence of Anti-Drug Antibody (ADA) to REGN10597 over time

    Time frame: Approximately 6 Years

  9. Magnitude of ADA to REGN10597 over time

    Time frame: Approximately 6 Years

07

Study locations

11 of 11 sites recruiting
08

References and documents

Related links

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Feb 2030, 64 months after the start.

Of 135 industry-sponsored phase 1/2 interventional studies under Melanoma, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 84. This study's planned 64 months is close to that.

Counting every sponsor, half of 220 studies reached it within 61 months; a quarter within 42 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2024
First posted
May 14, 2024
StartActual
Sep 23, 2024
Primary completionEst.
Feb 3, 2030
CompletionEst.
Feb 3, 2030
Last update
Apr 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06413680
Responsible party
Sponsor
First posted
May 14, 2024
Start date
Sep 23, 2024
Primary completion
Feb 3, 2030 (estimated)
Completion
Feb 3, 2030 (estimated)
Last update
Apr 28, 2026

Study contacts

Clinical Trials Administrator
Contact
clinicaltrials@regeneron.com
844-734-6643
Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cemiplimab

Start the discussion